Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) have been assigned a consensus rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $10.75.
A number of analysts have weighed in on the stock. ValuEngine raised shares of Cytori Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, September 4th. Zacks Investment Research raised shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Tuesday, July 31st. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Cytori Therapeutics in a research note on Wednesday, July 11th. Finally, Maxim Group cut shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th.
NASDAQ:CYTX traded up $0.01 during mid-day trading on Monday, reaching $0.36. The stock had a trading volume of 885,958 shares, compared to its average volume of 470,912. The stock has a market capitalization of $2.64 million, a price-to-earnings ratio of -0.05 and a beta of 2.42. Cytori Therapeutics has a 12 month low of $0.31 and a 12 month high of $5.40.
Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings data on Tuesday, August 14th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.09). The firm had revenue of $1.56 million during the quarter, compared to the consensus estimate of $2.50 million. Cytori Therapeutics had a negative net margin of 380.64% and a negative return on equity of 202.09%. As a group, sell-side analysts predict that Cytori Therapeutics will post -0.85 EPS for the current fiscal year.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.
Featured Story: What is the 52-week high/low?
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.